Brief: Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical

ASKA Pharmaceutical Holdings

27/02/2017 12:34

Feb 27 (Reuters) - Pieris Pharmaceuticals Inc  PI6.F  
    * Pieris signs partnership for anemia drug PRS-080, granting 
exclusive option in Japan to Aska Pharmaceutical 
    * Pieris Pharmaceuticals Inc - co will receive an immediate 
option payment of $2.75 million usd from Aska 
    * Pieris Pharmaceuticals Inc - a Phase 1 study conducted in 
healthy volunteers demonstrated that a single dose of PRS-080 
was well tolerated 
    * Pieris Pharmaceuticals Inc - Pieris may also receive 
double-digit royalties on net sales of PRS-080 up to mid- to 
high-teens 
    * Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin 
a first-in-human study around middle of 2017 
    * Pieris Pharmaceuticals Inc - PRS-343  scheduled to enter a 
first-in patient trial in first half of 2017 
    * Pieris Pharmaceuticals - should Aska exercise option, 
Pieris would be eligible for over $80 million usd in combined 
option exercise fee and milestones 
 
Source text for Eikon:  ID:nMKWgnpgYa  
Further company coverage:  PI6.F  
 
 ((Bangalore.newsroom@thomsonreuters.com;))